Biotech Values

[semi_infinite]

IMRA - the odds of failure for early bioscience stories has always been high and there are now even more "pre" preclinical publicly traded via SPACs and PIPEs.

Today’s $IMRA setback made me curious so I checked:

There are 163 biotech/drug stocks on U.S. exchanges (NYSE, AMEX, Nasdaq) valued at $50M or lower, per a Finviz screen.

288 bio/drug stocks with market caps $100M or less.

— Adam Feuerstein ✡️ (@adamfeuerstein) April 5, 2022